[A clinical study of associated @entity150 in XXXX with @entity703 ].

@entity1 @entity8 @entity150 @entity1606 @entity12825 @entity703
We investigated the incidence of associated @entity150 and prognosis in 101 cases with a pathological @entity1606 , selected from those with @entity703 whom we had encountered over the 18 years between April 1976 and March 1993. Among these 101 cases, the incidence of associated @entity150 was noted in 42 (41.6%), 23 (22.8%) with @entity12825 and 19 (18.8%) with subsequence. As for the primary site of @entity8 , the @entity12825 was 15.4% and subsequence 20.5% in renal pelvis, and the @entity12825 was 24.6% and subsequence 19.3% in ureter, and the @entity12825 was 60.0% and subsequence 0.0% in both @entity8 . The incidence of coexistent @entity150 was high in both @entity8 , but no significant difference was noted. As for the stage, the incidence of @entity12825 was high in T1, while subsequence was high in T2, but no significant difference was noted. As for the grade, the incidence of @entity12825 was high in G2, but no significant difference was noted. The 5 year survival rate was 58.2% in those without, 54.2% with @entity12825 , and 82.5% with subsequent @entity150 , with a significant difference (p < 0.05) between the last two groups. The interval of subsequent @entity150 ranged from 4 to 164 months (mean 27.7 months), with the incidence within 2 years being approximately 70.0%. It was found that the @entity703 are frequently associated @entity150 while associated @entity150 dose not appear to have an ill effect on the prognosis. Therefore it is necessary that @entity1 with @entity703 be observed closely for 5 years, especially for the initial 2 years.
